PillRx only · Injection · Intramuscular
Midazolam
Midazolam Hydrochloride
3 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US19 NDCs
3 active makers
3 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 8 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$0.349
Latest avg · Jul 22, 2026
-22%
Since Feb 19, 2025
3
Active US suppliers
91%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
43K
Rx · 2026 Q1
107K
Units dispensed
-30%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it3 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Hikma Pharmaceuticals USA Inc. | unknown | 17 | SUPPLYING |
| Henry Schein Inc. | unknown | 3 | SUPPLYING |
| Civica, Inc. | unknown | 2 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Apr 2, 2020SHORTAGEDrug shortage: Midazolam Hydrochloride Injection (Hikma Pharmaceuticals USA, Inc.)
Midazolam Hydrochloride Injection — reported in shortage by Hikma Pharmaceuticals USA, Inc.. Therapeutic category: Anesthesia, Neurology.